101. An Objective Short Sleep Insomnia Disorder Subtype Is Associated With Reduced Brain Metabolite Concentrations In Vivo: A Preliminary Magnetic Resonance Spectroscopy Assessment
- Author
-
M. A. Green, Christopher J. Gordon, Angela L. D'Rozario, Simon D. Kyle, Christopher B. Miller, Ronald R. Grunstein, Caroline Rae, Colin A. Espie, Brendon J. Yee, and Delwyn J. Bartlett
- Subjects
Adult ,Male ,medicine.medical_specialty ,Magnetic Resonance Spectroscopy ,Time Factors ,Glutamine ,Polysomnography ,Metabolite ,Glutamic Acid ,Prefrontal Cortex ,Creatine ,Gyrus Cinguli ,030218 nuclear medicine & medical imaging ,Young Adult ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Sleep Initiation and Maintenance Disorders ,Physiology (medical) ,Internal medicine ,Insomnia ,medicine ,Humans ,Sleep study ,Anterior cingulate cortex ,Aspartic Acid ,medicine.diagnostic_test ,business.industry ,Brain ,Middle Aged ,Endocrinology ,medicine.anatomical_structure ,chemistry ,Case-Control Studies ,Anesthesia ,Female ,Occipital Lobe ,Neurology (clinical) ,medicine.symptom ,Sleep onset ,Sleep ,business ,030217 neurology & neurosurgery - Abstract
Objectives To evaluate brain metabolites in objective insomnia subtypes defined from polysomnography (PSG): insomnia with short sleep duration (I-SSD) and insomnia with normal sleep duration (I-NSD), relative to good sleeping controls (GSCs). Methods PSG empirically grouped insomnia patients into I-SSD (n = 12: mean [SD] total sleep time [TST] = 294.7 minutes [30.5]) or I-NSD (n = 19: TST = 394.4 minutes [34.9]). 1H magnetic resonance spectroscopy (MRS) acquired in the left occipital cortex (LOCC), left prefrontal cortex, and anterior cingulate cortex was used to determine levels of creatine, aspartate, glutamate, and glutamine (referenced to water). Glutathione, glycerophosphocholine, lactate, myoinositol, and N-acetylaspartate measurements were also obtained. Sixteen GSCs were included for comparison. Multivariate analysis of variance was used to evaluate differences in creatine, aspartate, glutamate, and glutamine. Results Aspartate and glutamine concentrations were reduced in the LOCC in I-SSD compared with I-NSD (both p < .05, d = .80-.99). Creatine displayed a nonsignificant mean reduction in I-SSD compared with I-NSD (p = .05, d = .58). Glutamine was reduced in I-SSD compared with controls (p < .05, d = .93). There were no differences in metabolites between all (I-SSD and I-NSD) insomnia patients and controls. In patients with insomnia, LOCC glutamine concentrations were found to be positively correlated with TST (r = .43, p < .05) and negatively correlated with wake-time after sleep onset (r = -.40, p < .05). Conclusions Results indicate that I-SSD is associated with reduced brain metabolites in the LOCC compared with I-NSD and control concentrations of aspartate, glutamine, and creatine. Clinical Trial Registration Insomnia MRS imaging sleep study: Australia New Zealand Clinical Trials Registry (ANZCTR): https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12612000050853. Trial Identification Number 12612000050853.
- Published
- 2017
- Full Text
- View/download PDF